Camrelizumab Approved for Second-Line Liver Cancer Treatment in China
On March 4, Camrelizumab of Hengrui Medicine (SHR-1210) was approved for sale by the National Medical Products Administration (NMPA) in China for the second-line liver cancer treatment.
It was licensed for the second additional indication after it was approved for third-line Hodgkin's disease treatment in last May.
A PD-1 antibody developed by Hengrui Medicine, a drug of the same mechanism as OPDIVO of BMS and Keytruda of MSD.
Camrelizumab is a progressive second-line liver cancer treatment. As a monotherapy, it was approved for the results of phase 2 clinical trials, with 44.2% of Disease Control Rate (DCR), 14.7% of Objective Reaction Rate (ORR), and 55.9% of 12-month Overall Survival (OS), through the primary screening system.
As a first-line liver cancer treatment, Camrelizumab is undergoing a phase 3 global clinical trial with Elevar Therapeutics under fast track procedures in combination with Rivoceranib.
A total of 510 subjects from 14 countries, including the United States and China, are in progress, and in January, the number of patients recruited exceeded 20%.
Since the approval of Camrelizumab's second-line liver cancer treatment monotherapy has proven the safety and efficacy, the clinical progression has been further enhanced with expectations for the clinical outcome of the first-line liver cancer treatment currently in combination with Rivoceranib.